Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature

Leukemia Research

Volumn 34, Issue 7, 2010, Pages

  Abbi, Kamal K S ^a   Rizvi, Syed M ^a   Sivik, Jeffrey ^a   Thyagarajan, Subramanian ^a   Loughran, Thomas ^a   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALEMTUZUMAB; COTRIMOXAZOLE; CYANOCOBALAMIN; GLUCOSE; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

AGED; ASSISTED VENTILATION; BONE MARROW BIOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DEMYELINATION; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; ELECTROMYOGRAPHY; FLOW CYTOMETRY; GENE REARRANGEMENT; GUILLAIN BARRE SYNDROME; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIMB WEAKNESS; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PARESTHESIA; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN CEREBROSPINAL FLUID LEVEL; RESPIRATORY TRACT INTUBATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; AUTOIMMUNITY; COMBINED MODALITY THERAPY; COMPLEMENT PATHWAY, CLASSICAL; DENDRITIC CELLS; GLYCOPROTEINS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MALE; PLASMAPHERESIS; RESPIRATION, ARTIFICIAL; T-LYMPHOCYTE SUBSETS;

EID: 77952981525     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.036     Document Type: Letter

References (22)

1. Laros-van Gorkom B.A.P., Huisman C.A.M., Wijermans P.W., Schipperus M.R. Schipperus Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in The Netherlands. Neth J Med 2007, 65(9):333-337.
2. Kirk A.D., Hale D.A., Swanson S.J., Mannon R.B. Autoimmune thyroid Disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006, 6:1084-1085.
3. Loh Y., Oyama Y., Statkute L., Quigley K., Yaung K., Gonda E., et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007, 109:2643-3548.
4. Elimelakh M., Dayton V., Park K.S., Gruessner A.C., Sutherland D., Howe R.B., et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007, 92:1029-1036.
5. Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Dyer M.J., et al. Levels of expression of CD52 in normal and leukemic Band T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998, 22:185-191.
6. Hale G., Xia M.Q., Tighe H.P., Dyer M.J., Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35:118-127.
7. Dungarwalla m, Matutes E., Dearden C. E Prolymphocytic leukemia of B and T cell subtype-a state of the art paper. Eur J Hematol 2008, 80(June (6)):469-476.
8. Brett S., Baxter G., Cooper H., Johnston J.M., Tite J., Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996, 88:13-19.
9. Pérez-Simón J.A., Kottaridis P.D., Martino R., Craddock C., Caballero D., Chopra R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121-3127.
10. Carella C.C.A.M., Beltrami G., Scalzulli P.R., Carella A.M., Corsetti M.T. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004, 33:131-132.
11. Laurenti L., Piccioni P., Cattani P., Cingolani A., Efremov D., Chiusolo P., et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004, 89:1248-1252.
12. Ratzinger G., Reagan J.L., Heller G., Busam K.J., Young J.W. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003, 101:1422-1429. [Erratum in: Blood 2005;105:3018].
13. Buggins A.G.S., Mufti G.J., Salisbury J., Codd J., Westwood N., Arno M., et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002, 100:1715-1720.
14. Rutella S., Lemoli R.M. Regulatory T cells and tolerogenic dendritic cells: from basicbiology to clinical applications. Immunol Lett 2004, 94:11-26.
15. Kubach J., Becker C., Schmitt E., Steinbrink K., Huter E., Tuettenberg A., et al. Dendritic cells: sentinels of immunity and tolerance. Int J Hematol 2005, 81:197-203.
16. Johansson S., Berg L., Hall H., Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol 2005, 26:613-618.
17. Cox A.L., Thompson S.A., Jones J.L., Robertson V.H., Hale G., Waldmann H., et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005, 35:3332-3342.
18. Clatworthy M.R., Jayne D.R. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab. Am J Kidney Dis 2006, 47:680-682.
19. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007, 204:1959-1971.
20. Carmona A., Alonso J.D., de las Heras M., Navarrete A. Guillain-Barré syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?. Clin Transl Oncol 2006, 8:764-766.
21. Jaso R., Sierra M., Calleja J., Valero C. Pascual-Guillain-Barré Julio syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?. J Neurol 2009, (November).
22. Castelli R., Moreo G., Panfili B., Cogiamanian F., Reda G., Cortelezzi A., et al. Guillain-Barré syndrome in a chronic lymphocytic leukaemia (CLL) patient after subcutaneous alemtuzumab and high dose of prednisone therapy. J Peripher Nerv Syst 2009, 14(Supplement):1-28.